Literature DB >> 27087961

Type 1 serrated polyposis represents a predominantly female disease with a high prevalence of dysplastic serrated adenomas, without germline mutation in MUTYH, APC, and PTEN genes.

Marco Petronio1, Stephane Pinson2, Thomas Walter1, Marie-Odile Joly3, Valerie Hervieu3, Julien Forestier1, Jean-Christophe Saurin1.   

Abstract

AIM: The aim of this article is to clarify the epidemiologic, clinical, endoscopic, biological and genetic characteristics of type 1 serrated polyposis patients. PATIENTS AND METHODS: Consecutive patients responding to the WHO definition of type 1 serrated polyposis in one reference center for polyposis patients accepted genetic counseling. Detailed data on previous endoscopies, histology, and life habits were recorded, after informed consent, germline analysis of MUTYH, APC, and PTEN germline mutations. Molecular biology was tested on available fixed tissue from different lesion types.
RESULTS: We included 29 patients (mean age 53.5 years, 21 women (72.4%)), four with a personal history of colorectal cancer (CRC), with a mean of 11.6 SSAs, with associated hyperplastic polyps in 93.1% and adenomas in 82.8%. SSAs showed no dysplasia in 46.9% of lesions (three of 29 patients), LGD in 51.9% (22/29 patients), and HGD in 1.2% (four of 29 patients). Dysplasia was more frequent in proximal SSAs and in women. Colectomy 15 patients (51.7%), upper digestive neoplasms: eight patients (27.5%); smokers: 24 patients (82.8%); family history of CRC: 16 patients (55.2%). Biology: MSI-H phenotype in one SSA, V600E BRAF mutation in 95% of SSAs; MGMT hypermethylation in three of 17 SSAs. No germline mutation was detected in MYH, APC or PTEN genes.
CONCLUSION: Type 1 serrated polyposis corresponds to a majority of women, with a high prevalence of smokers, a high prevalence of dysplastic serrated adenomas, particularly in females, without identified germline mutation in targeted predisposing genes.

Entities:  

Keywords:  Polyposis; endoscopy; epidemiology; genetics; molecular biology; sessile serrated adenomas

Year:  2015        PMID: 27087961      PMCID: PMC4804363          DOI: 10.1177/2050640615594939

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  21 in total

Review 1.  Gastrointestinal polyposes: clinical, pathological and molecular features.

Authors:  Jeremy R Jass
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

2.  Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas.

Authors:  Manish K Gala; Yusuke Mizukami; Long P Le; Kentaro Moriichi; Thomas Austin; Masayoshi Yamamoto; Gregory Y Lauwers; Nabeel Bardeesy; Daniel C Chung
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

3.  BRAF mutations in aberrant crypt foci and hyperplastic polyposis.

Authors:  Robyn Beach; Annie On-On Chan; Tsung-Teh Wu; Jill A White; Jeffrey S Morris; Simon Lunagomez; Russell R Broaddus; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

4.  High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.

Authors:  Kevin J Spring; Zhen Zhen Zhao; Rozemary Karamatic; Michael D Walsh; Vicki L J Whitehall; Tanya Pike; Lisa A Simms; Joanne Young; Michael James; Grant W Montgomery; Mark Appleyard; David Hewett; Kazutomo Togashi; Jeremy R Jass; Barbara A Leggett
Journal:  Gastroenterology       Date:  2006-08-18       Impact factor: 22.682

5.  Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.

Authors:  Brandie Heald; Jessica Mester; Lisa Rybicki; Mohammed S Orloff; Carol A Burke; Charis Eng
Journal:  Gastroenterology       Date:  2010-06-27       Impact factor: 22.682

6.  Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study.

Authors:  P Lage; M Cravo; R Sousa; P Chaves; M Salazar; R Fonseca; I Claro; A Suspiro; P Rodrigues; H Raposo; P Fidalgo; C Nobre-Leitão
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

Review 7.  Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review.

Authors:  Angel Ferrández; Wade Samowitz; James A DiSario; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

8.  Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study.

Authors:  Karam S Boparai; Elisabeth M H Mathus-Vliegen; Jan J Koornstra; Fokko M Nagengast; Monique van Leerdam; Carel J M van Noesel; Martin Houben; Annemieke Cats; Liselotte P van Hest; Paul Fockens; Evelien Dekker
Journal:  Gut       Date:  2009-08-25       Impact factor: 23.059

9.  Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis.

Authors:  Karam S Boparai; Evelien Dekker; Susanne Van Eeden; Mirjam M Polak; Joep F W M Bartelsman; Elisbeth M H Mathus-Vliegen; Josbert J Keller; Carel J M van Noesel
Journal:  Gastroenterology       Date:  2008-09-20       Impact factor: 22.682

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  2 in total

Review 1.  Hereditary or Not? Understanding Serrated Polyposis Syndrome.

Authors:  Peter P Stanich; Rachel Pearlman
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

2.  Germline variant testing in serrated polyposis syndrome.

Authors:  Aisling Murphy; Joyce Solomons; Peter Risby; Jessica Gabriel; Tina Bedenham; Michael Johnson; Nathan Atkinson; Adam A Bailey; Elizabeth Bird-Lieberman; Simon J Leedham; James E East; Sujata Biswas
Journal:  J Gastroenterol Hepatol       Date:  2022-02-18       Impact factor: 4.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.